NZ702914A - Ite for cancer intervention and eradication - Google Patents

Ite for cancer intervention and eradication

Info

Publication number
NZ702914A
NZ702914A NZ702914A NZ70291410A NZ702914A NZ 702914 A NZ702914 A NZ 702914A NZ 702914 A NZ702914 A NZ 702914A NZ 70291410 A NZ70291410 A NZ 70291410A NZ 702914 A NZ702914 A NZ 702914A
Authority
NZ
New Zealand
Prior art keywords
ylcarbonyl
indol
cancer
thiazole
methyl
Prior art date
Application number
NZ702914A
Other languages
English (en)
Inventor
Jiasheng Song
Original Assignee
Ahr Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ahr Pharmaceuticals Inc filed Critical Ahr Pharmaceuticals Inc
Publication of NZ702914A publication Critical patent/NZ702914A/en

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E04—BUILDING
    • E04D—ROOF COVERINGS; SKY-LIGHTS; GUTTERS; ROOF-WORKING TOOLS
    • E04D1/00—Roof covering by making use of tiles, slates, shingles, or other small roofing elements
    • E04D1/30—Special roof-covering elements, e.g. ridge tiles, gutter tiles, gable tiles, ventilation tiles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L75/00—Compositions of polyureas or polyurethanes; Compositions of derivatives of such polymers
    • C08L75/04—Polyurethanes
    • E—FIXED CONSTRUCTIONS
    • E04—BUILDING
    • E04D—ROOF COVERINGS; SKY-LIGHTS; GUTTERS; ROOF-WORKING TOOLS
    • E04D1/00—Roof covering by making use of tiles, slates, shingles, or other small roofing elements
    • E04D1/12—Roofing elements shaped as plain tiles or shingles, i.e. with flat outer surface
    • E04D1/20—Roofing elements shaped as plain tiles or shingles, i.e. with flat outer surface of plastics; of asphalt; of fibrous materials
    • E—FIXED CONSTRUCTIONS
    • E04—BUILDING
    • E04D—ROOF COVERINGS; SKY-LIGHTS; GUTTERS; ROOF-WORKING TOOLS
    • E04D1/00—Roof covering by making use of tiles, slates, shingles, or other small roofing elements
    • E04D1/28—Roofing elements comprising two or more layers, e.g. for insulation
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02S—GENERATION OF ELECTRIC POWER BY CONVERSION OF INFRARED RADIATION, VISIBLE LIGHT OR ULTRAVIOLET LIGHT, e.g. USING PHOTOVOLTAIC [PV] MODULES
    • H02S20/00—Supporting structures for PV modules
    • H02S20/20—Supporting structures directly fixed to an immovable object
    • H02S20/22—Supporting structures directly fixed to an immovable object specially adapted for buildings
    • H02S20/23—Supporting structures directly fixed to an immovable object specially adapted for buildings specially adapted for roof structures
    • H02S20/25—Roof tile elements
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2101/00—Manufacture of cellular products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02B—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO BUILDINGS, e.g. HOUSING, HOUSE APPLIANCES OR RELATED END-USER APPLICATIONS
    • Y02B10/00—Integration of renewable energy sources in buildings
    • Y02B10/10—Photovoltaic [PV]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E10/00—Energy generation through renewable energy sources
    • Y02E10/50—Photovoltaic [PV] energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Architecture (AREA)
  • Civil Engineering (AREA)
  • Structural Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ702914A 2009-11-02 2010-10-14 Ite for cancer intervention and eradication NZ702914A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25742209P 2009-11-02 2009-11-02
NZ599896A NZ599896A (en) 2009-11-02 2010-10-14 Itse for cancer intervention and eradication

Publications (1)

Publication Number Publication Date
NZ702914A true NZ702914A (en) 2016-05-27

Family

ID=43922453

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ599896A NZ599896A (en) 2009-11-02 2010-10-14 Itse for cancer intervention and eradication
NZ702914A NZ702914A (en) 2009-11-02 2010-10-14 Ite for cancer intervention and eradication

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ599896A NZ599896A (en) 2009-11-02 2010-10-14 Itse for cancer intervention and eradication

Country Status (9)

Country Link
US (6) US8604067B2 (enExample)
EP (2) EP3689347A1 (enExample)
JP (1) JP5598775B2 (enExample)
CN (2) CN106588908A (enExample)
AU (1) AU2010313622B2 (enExample)
CA (1) CA2776319C (enExample)
ES (1) ES2791684T3 (enExample)
NZ (2) NZ599896A (enExample)
WO (1) WO2011053466A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9630947B2 (en) 2009-12-31 2017-04-25 Otsuka Pharmaceutical Co., Ltd. Therapeutic compounds and related methods of use

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
AU2010313622B2 (en) 2009-11-02 2014-08-14 Ahr Pharmaceuticals, Inc. ITE for cancer intervention and eradication
US10632106B2 (en) 2009-11-02 2020-04-28 Ariagen, Inc. Methods of cancer treatment with 2-(1′H-Indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester
CN107001350B (zh) 2014-09-12 2021-04-09 阿里根公司 2-(1’h-吲哚-3’-羰基)-噻唑-4-羧酸甲酯及其结构类似物的有效且可扩展的合成
EP3274053A4 (en) 2015-03-23 2018-12-05 The Brigham and Women's Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
CN113480530A (zh) * 2016-12-26 2021-10-08 阿里根公司 芳香烃受体调节剂
TWI752155B (zh) * 2017-02-01 2022-01-11 德商菲尼克斯製藥股份有限公司 芳香烴受體(AhR)調節劑化合物
TWI674260B (zh) * 2017-02-01 2019-10-11 德商菲尼克斯製藥股份有限公司 芳基烴受體(AhR)調節劑化合物
US11459322B2 (en) 2017-11-20 2022-10-04 Ariagen, Inc. Indole compounds and their use
CN113906021A (zh) 2019-04-15 2022-01-07 阿里根公司 手性吲哚化合物及其用途
US11136318B2 (en) 2019-06-21 2021-10-05 Noramco, Llc Processes for the preparation of aryl hydrocarbon receptor ligands
US20210300912A1 (en) 2019-12-20 2021-09-30 Ikena Oncology, Inc. Aryl hydrocarbon receptor (ahr) agonists and uses thereof
JP2023508909A (ja) 2019-12-20 2023-03-06 イケナ オンコロジー， インコーポレイテッド 例えば血管新生関連障害または炎症性疾患の処置に向けたアリール炭化水素受容体（ａｈｒ）アゴニストとしての４－フェニル－ｎ－（フェニル）チアゾール－２－アミン誘導体及び関連化合物
CN111067895A (zh) * 2020-01-14 2020-04-28 广东医科大学 Ite在制备预防和/或治疗心肺循环系统疾病的药物中的应用
WO2022133480A1 (en) 2020-12-18 2022-06-23 Ikena Oncology, Inc. Aryl hydrocarbon receptor (ahr) agonists and uses thereof
EP4219501A4 (en) * 2021-05-27 2024-08-28 Shandong University COMPOUND CONTAINING 2,4-THIAZOLE RING, PREPARATION METHOD THEREOF AND USE THEREOF

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811425A (en) 1997-03-04 1998-09-22 Abbott Laboratories Heterocyclic compounds as COX-2 inhibitors
US7709520B2 (en) 2000-10-06 2010-05-04 The Texas A&M University System Diindolylmethane and C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers
US7002019B2 (en) 2002-02-12 2006-02-21 Wisconsin Alumni Research Foundation Synthesis of indole thiazole compounds as ligands for the Ah receptor
ES2327615T3 (es) * 2001-02-14 2009-11-02 Wisconsin Alumni Research Foundation Preparaciones y uso de un ligando receptor de ah, ester metilico del acido 2-(1'h-indol-3'-carbonil)-tiazol-4-carboxilico.
US7419992B2 (en) 2001-02-14 2008-09-02 Wisconsin Alumni Research Foundation Use of aryl hydrocarbon receptor ligand as a therapeutic intervention in angiogenesis-implicated disorders
US20020177594A1 (en) 2001-03-14 2002-11-28 Curtin Michael L. Inhibitors of histone deacetylase
TW200412344A (en) 2003-01-02 2004-07-16 Hoffmann La Roche Novel CB 1 receptor inverse agonists
TW200621766A (en) 2004-09-17 2006-07-01 Hoffmann La Roche Substituted hydantoins
EP1842541A1 (en) * 2006-03-29 2007-10-10 G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg Plant components and extracts and uses thereof
JP2011503232A (ja) * 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
US20090142832A1 (en) * 2007-11-29 2009-06-04 James Dalton Indoles, Derivatives, and Analogs Thereof and Uses Therefor
CA2755933A1 (en) * 2008-03-21 2009-09-24 The Brigham And Women's Hospital, Inc. Modulation of the immune response
AU2010313622B2 (en) 2009-11-02 2014-08-14 Ahr Pharmaceuticals, Inc. ITE for cancer intervention and eradication
US20130338201A1 (en) 2009-11-02 2013-12-19 Ahr Pharmaceuticals, Inc. Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester
MX2014002285A (es) 2011-08-26 2017-01-06 Southern Res Inst Inhibidores de la replicacion del vih.
US9073881B2 (en) 2011-09-23 2015-07-07 Hoffmann-La Roche Inc. Benzoic acid derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9630947B2 (en) 2009-12-31 2017-04-25 Otsuka Pharmaceutical Co., Ltd. Therapeutic compounds and related methods of use

Also Published As

Publication number Publication date
AU2010313622B2 (en) 2014-08-14
US20200323827A1 (en) 2020-10-15
AU2010313622A1 (en) 2012-05-31
NZ599896A (en) 2015-09-25
WO2011053466A1 (en) 2011-05-05
US9694000B2 (en) 2017-07-04
US9238645B2 (en) 2016-01-19
CA2776319A1 (en) 2011-05-05
US20190275011A1 (en) 2019-09-12
EP3689347A1 (en) 2020-08-05
CA2776319C (en) 2018-01-02
US20170333401A1 (en) 2017-11-23
EP2496081A1 (en) 2012-09-12
EP2496081B1 (en) 2020-03-25
CN102573470A (zh) 2012-07-11
CN106588908A (zh) 2017-04-26
EP2496081A4 (en) 2013-05-01
US20160136139A1 (en) 2016-05-19
ES2791684T3 (es) 2020-11-05
US10195182B2 (en) 2019-02-05
JP2013509411A (ja) 2013-03-14
JP5598775B2 (ja) 2014-10-01
US20130310429A1 (en) 2013-11-21
US8604067B2 (en) 2013-12-10
US20120214853A1 (en) 2012-08-23

Similar Documents

Publication Publication Date Title
NZ702914A (en) Ite for cancer intervention and eradication
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
MX2009011867A (es) Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
MX2009012613A (es) Tiazoles substituidos por heteroarilo y su uso como agentes antivirales.
MX2010002820A (es) Analogos de tiazolidindiona para tratamiento de hipertension.
NZ602099A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
MX2012003171A (es) Novedosos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
GEP20156389B (en) Oxazolidin-2-one compounds and their usage as pi3ks inhibitors
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
MY148690A (en) Novel macrocyclic inhibitors of hepatitis c virus replication
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
JP2008535903A5 (enExample)
EA201270570A1 (ru) Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90
TN2009000481A1 (en) Novel peptide inhibitors of hepatitis c virus replication
ZA201002690B (en) N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
NZ585370A (en) Viral polymerase inhibitors
JP2008535902A5 (enExample)
MX2010008699A (es) Derivados heterociclicos como inhibidores de virus de la hepatitis c.
NZ543897A (en) Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases
MX2009009473A (es) Compuestos para el tratamiento de hepatitis c.
MD20150075A2 (ro) Compuşi tetraciclici heterociclu-substituiţi şi metode de utilizare a acestora pentru tratamentul bolilor virale
MX2009009238A (es) Nuevos inhibidores de fosfodiesterasa.
UA104148C2 (ru) [4-(5-аминометил-2-фторфенил)-пиперидин-1-ил]-[7-фтор-1-(2-метоксиэтил)-4-трифторметокси-1h-индол-3-ил]-метанон как ингибитор триптазы тучных клеток
MX2012000177A (es) 2-carboxamida-cicloamino-ureas sustituidas.

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE FILED DATE HAS BEEN CORRECTED TO 10/12/2014; THE PATENT COMPLETE SPECIFICATION DATE HAS BEEN CORRECTED TO 10/12/2014

Effective date: 20150108

ASS Change of ownership

Owner name: AHR PHARMACEUTICALS, INC, US

Effective date: 20150903

ERR Error or correction

Free format text: THE FILED DATE HAS BEEN CORRECTED TO 14/10/2010; THE PATENT COMPLETE SPECIFICATION DATE HAS BEEN CORRECTED TO 14/10/2010

Effective date: 20151127

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 OCT 2017 BY MARY WEGNER

Effective date: 20160908

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2018 BY COMPUTER PACKAGES INC

Effective date: 20170920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2019 BY COMPUTER PACKAGES INC

Effective date: 20180918

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2020 BY COMPUTER PACKAGES INC

Effective date: 20190918

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2021 BY COMPUTER PACKAGES INC

Effective date: 20200918

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2022 BY COMPUTER PACKAGES INC

Effective date: 20210917

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2023 BY COMPUTER PACKAGES INC

Effective date: 20220930

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2024 BY COMPUTER PACKAGES INC

Effective date: 20230930

LAPS Patent lapsed